FDA Regulatory

FDA regulatory action shapes the entire GLP-1 market. Compounded availability depends on 503A bulks list inclusion. New formulations require fresh approval pathways. Shortage status determines what 503A pharmacies can legally produce. We track active FDA proposals, comment periods, and final rules with focus on patient-side impact.